Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

OBJECTIVE: To investigate the efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). METHODS: In a multicentre, placebo-controlled phase 3 study (NCT02985983) conducted at 48 sites across Japan, Korea and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, James Cheng-Chung, Kim, Tae-Hwan, Kishimoto, Mitsumasa, Ogusu, Naoki, Jeong, Haeyoun, Kobayashi, Shigeto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292606/
https://www.ncbi.nlm.nih.gov/pubmed/33827787
http://dx.doi.org/10.1136/annrheumdis-2020-219406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292606/
https://www.ncbi.nlm.nih.gov/pubmed/33827787
http://dx.doi.org/10.1136/annrheumdis-2020-219406

Ejemplares similares